Squarepoint
AUPH icon

Squarepoint’s Aurinia Pharmaceuticals AUPH Stock Holding History

Squarepoint’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.39M Sell
317,430
-2,374
-0.7% -$37.9K 0.01% 1549
2026
Q1 		$4.74M Sell
319,804
-124,223
-28% -$1.82M 0.01% 1549
2025
Q4 		$7.08M Sell
444,027
-111,670
-20% -$1.58M 0.01% 1246
2025
Q3 		$6.14M Buy
555,697
+71,760
+15% +$784K 0.01% 1339
2025
Q2 		$4.1M Buy
483,937
+320,124
+195% +$2.57M ﹤0.01% 1597
2025
Q1 		$1.32M Buy
163,813
+47,216
+40% +$383K ﹤0.01% 2427
2024
Q4 		$1.05M Buy
+116,597
New +$951K ﹤0.01% 3027
2023
Q3 		– Sell
-22,941
Closed -$222K – 3769
2023
Q2 		$222K Buy
22,941
+3,545
+18% +$36.8K ﹤0.01% 3149
2023
Q1 		$213K Sell
19,396
-20,267
-51% -$179K ﹤0.01% 2770
2022
Q4 		$171K Buy
39,663
+4,667
+13% +$27.1K ﹤0.01% 2835
2022
Q3 		$263K Buy
+34,996
New +$303K ﹤0.01% 2553
2022
Q2 		– Sell
-227,114
Closed -$2.81M – 2867
2022
Q1 		$2.81M Buy
227,114
+134,933
+146% +$2.09M 0.01% 952
2021
Q4 		$2.11M Buy
92,181
+46,428
+101% +$1.1M 0.01% 1227
2021
Q3 		$1.01M Buy
+45,753
New +$726K ﹤0.01% 1554
2020
Q2 		– Sell
-35,084
Closed -$509K – 2220
2020
Q1 		$509K Buy
35,084
+5,989
+21% +$106K 0.01% 1029
2019
Q4 		$589K Buy
+29,095
New +$268K ﹤0.01% 1669

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's AUPH Position: Q2 2026 in Review

Squarepoint reduced its Aurinia Pharmaceuticals (AUPH) stake by 0.74% in Q2 2026, selling an estimated $37.9K and leaving 317,430 shares worth $5.39M. The position accounts for 0.01% of the portfolio, ranked #1549.

Squarepoint first reported a position in AUPH in Q4 2019 and has held it in 16 quarters since. The position peaked at $7.08M in Q4 2025. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Squarepoint held 317,430 shares of Aurinia Pharmaceuticals worth $5.39M as of Q2 2026.
  • Squarepoint sold 2,374 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $37.9K.
  • Aurinia Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1549 holding.
  • Squarepoint first reported a position in Aurinia Pharmaceuticals in Q4 2019 and has held it in 16 quarters since.
  • Squarepoint's Aurinia Pharmaceuticals position peaked at $7.08M in Q4 2025.
  • 283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.